Skip to main content

Table 3 Active injury score, regeneration score, and chronicity score in OSOM of different experimental groups (n = 20 and n = 5 for days subgroups, mean ± SD)

From: Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats

 

Group I

Group II

Group III

Group IV

Group V

Group VI

negative control

cisplatin ‘CDDP’-treated

cisplatin + rBMSCs-treated

cisplatin + hADSCs-treated (n = 20)

cisplatin + hAFSCs-treated

cisplatin + DMEM culture media-treated

Active injury

 Day 4

0.0 (0.0–0.0)

7.0 (7.0–7.0)a

3.0 (2.0–3.0)ab

3.0 (2.0–3.0)ab

3.0 (2.0–3.0)ab

6.0 (6.0–7.0)abcde

 Day 7

0.0 (0.0–0.0)

6.0 (6.0–6.0)a

3.0 (3.0–3.0)ab

3.0 (2.0–3.0)ab

3.0 (2.0–3.0)ab

6.0 (6.0–6.0)abcde

 Day 11

0.0 (0.0–0.0)

4.0 (4.0–4.0)a

1.0 (1.0–1.0)ab

1.0 (1.0–1.0)ab

1.0 (1.0–1.0)ab

6.0 (5.0–6.0)abcde

 Day 30

0.0 (0.0–0.0)

4.0 (4.0–4.0)a

1.0 (0.0–1.0)b

1.0 (1.0–1.0)b

1.0 (1.0–1.0)ab

3.0 (3.0–3.0)abcde

Regeneration

 Day 4

0.0 (0.0–0.0)

0.0 (0.0–0.0)

4.0 (4.0–5.0)ab

4.0 (4.0–5.0)ab

4.0 (3.0–5.0)ab

0.0 (0.0–0.0)cde

 Day 7

0.0 (0.0–0.0)

0.0 (0.0–0.0)

6.0 (5.0–6.0)ab

6.0 (6.0–6.0)ab

7.0 (6.0–7.0)abc

0.0 (0.0–0.0)cde

 Day 11

0.0 (0.0–0.0)

1.0 (1.0–2.0)a

8.0 (7.0–8.0)ab

8.0 (7.0–9.0)ab

8.0 (8.0–8.0)ab

1.0 (1.0–2.0)acde

 Day 30

0.0 (0.0–0.0)

3.0 (3.0–3.0)a

9.0 (8.0–9.0)ab

8.0 (7.0–9.0)ab

8.0 (7.0–9.0)ab

3.0 (3.0–3.0)acde

Chronicity

 Day 4

0.0 (0.0–0.0)

3.0 (3.0–3.0)a

2.0 (1.0–2.0)ab

2.0 (1.0–2.0)ab

2.0 (2.0–2.0)ab

3.0 (3.0–3.0)acde

 Day 7

0.0 (0.0–0.0)

4.0 (4.0–4.0)a

2.0 (2.0–3.0)ab

2.0 (2.0–2.0)ab

2.0 (2.0–2.0)ab

4.0 (4.0–5.0)acde

 Day 11

0.0 (0.0–0.0)

5.0 (5.0–5.0)a

2.0 (2.0–2.0)ab

2.0 (2.0–2.0)ab

2.0 (2.0–2.0)ab

5.0 (5.0–5.0)acde

 Day 30

0.0 (0.0–0.0)

3.0 (3.0–4.0)a

2.0 (2.0–2.0)ab

2.0 (2.0–2.0)ab

2.0 (2.0–2.0)ab

3.0 (3.0–3.0)acde

  1. Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Kruskal-Wallis test
  2. OSOM outer strip of outer medulla, rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium
  3. aSignificant difference vs. negative control group bSignificant difference vs. cisplatin-treated group cSignificant difference vs. cisplatin + rBMSCs-treated group dSignificant difference vs. cisplatin + hADSCs-treated group eSignificant difference vs. cisplatin + hAFSCs-treated group